This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daluge, S M
Right arrow Articles by Roberts, G B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daluge, S M
Right arrow Articles by Roberts, G B

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 July; 38(7): 1590-1603

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

S M Daluge, D J Purifoy, P M Savina, M H St Clair, N R Parry, I K Dev, P Novak, K M Ayers, J E Reardon and G B Roberts

Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.

ABSTRACT

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83) is a selective anti-human immunodeficiency virus (HIV) agent. When tested in phytohemagglutinin-stimulated normal human peripheral blood lymphocytes against fresh clinical isolates of HIV type 1 (HIV-1) obtained from patients naive to AZT (3'-azido-3'-deoxythymidine [zidovudine]), 935U83 inhibited virus growth with an average 50% inhibitory concentration (IC50) of 1.8 microM; corresponding IC50s were 0.10 microM for FLT (3'-deoxy-3'-fluorothymidine) and 0.23, 0.49, and 0.03 microM for the approved agents AZT, ddI (2',3'-dideoxyinosine), and ddC (2',3'-dideoxycytosine), respectively. Importantly, 935U83 retained activity against HIV strains that were resistant to AZT, ddI, or ddC. Of additional interest, we were unable to generate virus which was resistant to 935U83 by passaging either HXB2 (AZT-sensitive) or RTMC (AZT-resistant) strains in the presence of high concentrations of 935U83. The anabolic profile of 935U83 was similar to that of AZT, and 935U83 triphosphate was a potent inhibitor of HIV-1 reverse transcriptase. Pharmacokinetic evaluation showed good oral bioavailability (86% in mice and 60% in monkeys) and less extensive metabolism to the glucuronide relative to AZT. 935U83 showed low toxicity. In an in vitro assay for toxicity to a human erythrocyte progenitor, erythroid burst-forming unit (BFU-E), the IC50 for 935U83 (> 400 microM) was more than 1,000-fold those of FLT (0.07 microM) and AZT (0.30 microM). Mild reversible reductions in erythrocytes and associated parameters were seen in mice dosed orally with 2,000 mg of 935U83 per kg per day for 1 and 6 months. In monkeys dosed orally with up to 700 mg/kg/day for 1 and 6 months, the only possible treatment-related finding was cataracts in 1 of 12 animals given the intermediate dose of 225 mg/kg/day. At the highest doses in mice and monkeys, maximal concentrations in plasma were more than 100-fold the anti-HIV IC50s against clinical isolates. This safety profile in animals compares very favorably with that of any of the anti-HIV drugs approved to date and has led us to begin evaluation of 935U83 in patients with HIV infection.

Antimicrob Agents Chemother. 1994 July; 38(7): 1590-1603




This article has been cited by other articles:

  • Goffinet, C., Allespach, I., Oberbremer, L., Golden, P. L., Foster, S. A., Johns, B. A., Weatherhead, J. G., Novick, S. J., Chiswell, K. E., Garvey, E. P., Keppler, O. T. (2009). Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo. J. Virol. 83: 7706-7717 [Abstract] [Full Text]  
  • Garvey, E. P., Johns, B. A., Gartland, M. J., Foster, S. A., Miller, W. H., Ferris, R. G., Hazen, R. J., Underwood, M. R., Boros, E. E., Thompson, J. B., Weatherhead, J. G., Koble, C. S., Allen, S. H., Schaller, L. T., Sherrill, R. G., Yoshinaga, T., Kobayashi, M., Wakasa-Morimoto, C., Miki, S., Nakahara, K., Noshi, T., Sato, A., Fujiwara, T. (2008). The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral. Antimicrob. Agents Chemother. 52: 901-908 [Abstract] [Full Text]  
  • Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L. (2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother. 51: 3147-3154 [Abstract] [Full Text]  
  • Hazen, R. J., Harvey, R. J., St. Clair, M. H., Ferris, R. G., Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R., Short, S. A., Romines, K. R., Chan, J. H., Boone, L. R. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for Resistance. Antimicrob. Agents Chemother. 49: 4465-4473 [Abstract] [Full Text]  
  • Naesens, L., Lenaerts, L., Andrei, G., Snoeck, R., Van Beers, D., Holy, A., Balzarini, J., De Clercq, E. (2005). Antiadenovirus Activities of Several Classes of Nucleoside and Nucleotide Analogues. Antimicrob. Agents Chemother. 49: 1010-1016 [Abstract] [Full Text]  
  • Lai, Y., Tse, C.-M., Unadkat, J. D. (2004). Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs. J. Biol. Chem. 279: 4490-4497 [Abstract] [Full Text]  
  • Lee, K., Chu, C. K. (2001). Molecular Modeling Approach to Understanding the Mode of Action of L-Nucleosides as Antiviral Agents. Antimicrob. Agents Chemother. 45: 138-144 [Abstract] [Full Text]  
  • Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K., Pagano, J. S. (1999). Inhibition of Epstein-Barr Virus Replication by a Benzimidazole L-Riboside: Novel Antiviral Mechanism of 5,6-Dichloro-2-(Isopropylamino)-1-beta -L-Ribofuranosyl-1H-Benzimidazole. J. Virol. 73: 7271-7277 [Abstract] [Full Text]  
  • Eriksson, S., Xu, B., Clayton, D. A. (1995). Efficient Incorporation of Anti-HIV Deoxynucleotides by Recombinant Yeast Mitochondrial DNA Polymerase. J. Biol. Chem. 270: 18929-18934 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»